bioRxivMicrobiologyPreprint
EBV Triggers a Distinct Antiviral Response in HMC3 Cells
Noah E. BerkowitziD, Alexander Nosov, Mark Nosov, Fryda Solis RoldaniD, Anuj AhujaiD, Miranda McGaskey, Ethel CesarmaniD, Douglas F. NixoniD, Nicholas DopkinsiD
Abstract
Epstein-Barr Virus (EBV) is a gamma herpesvirus found in >90% of the world population that is associated with primary central nervous system (CNS) malignancy development in immunocompromised people. To provide mechanistic links between EBV infection and CNS malignancies, we investigated the capacity for EBV particles to suppress anti-tumor immunity in human microglia through a cell line model. With this approach, we exposed HMC3 cells to EBV-derived glycoprotein 350 (GP350), UV-inactivated EBV (UVi-EBV), and lipoteichoic acid (LTA) for up to 72 hours. Acute impacts of EBV particles and glycoprotein on microglial physiology were characterized at various timepoints in this model through measures of cytokine production, mRNA expression, and endocytosis. We found that UVi-EBV exposure significantly suppressed microglial production of anti-tumor interferons (IFNs) and upregulated microglial expression of the proto-oncogenic immediate early genes FOS and EGR1. Notably, there was no impairment of microglial endocytic functions following UVi-EBV stimulation, suggesting a compartmentalized suppression on IFN signaling. Overall, these findings reveal that the EBV-mediated inhibition of microglial IFN production may contribute to CNS malignancies and emphasize the urgency of innovating therapeutic strategies which target EBV to restore microglial anti-tumoral immunity. ImportanceEvidence linking EBV infection with primary CNS lymphomas and leiomyosarcomas are abundant, yet it is unclear whether EBV infection influences the CNS microenvironment and whether these effects then promote tumorigenesis. This study demonstrates evidence for EBV particle exposure to influence microglial immune phenotypes by suppressing IFN production, providing a putative mechanism for EBV virion expression in the CNS to suppress anti-tumoral immunity against EBV+ cancers. These results are particularly relevant to the etiology of EBV+ primary CNS cancers in immunocompromised people, where microglial play a heightened role in protecting the CNS in the absence of adaptive immunity.
- organism: human
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multiple viral microRNAs regulate interferon release and signaling early during infection with Epstein-Barr virus
M. Bouvet, S. Voigt, … W. Hammerschmidt·bioRxiv·Dec 3, 2020
- A bivalent EBV vaccine induces neutralizing antibodies that block B and epithelial cell infection and confer immunity in humanized mice
C.-J. Wei, W. Bu, … G. J. Nabel·bioRxiv·Jan 18, 2022
- EPSTEIN-BARR VIRUS LMP1 ENHANCES LEVELS OF MICROVESICLE-ASSOCIATED PD-L1
D. G. Meckes, M. A. Harb, L. Sun·bioRxiv·Jan 14, 2022
- EBV INFECTION OUTCOMES DETERMINED BY MONOCYTE AND TREG-DRIVEN IMMUNE DYNAMICS IN AN EX VIVO PBMC MODEL
Leena Yoon, Lauren N. MacMullen, … Paul M. Lieberman·bioRxiv·Nov 20, 2025
- The primary and secondary immune response to Epstein-Barr virus infection of human tonsil organoids
Álvaro F. García-Jiménez, Luis Ignacio González-Granado, … Hugh T. Reyburn·bioRxiv·Jan 16, 2026
- Ebola Virus Sequesters IRF3 in Viral Inclusion Bodies to Evade Host Antiviral Immunity